“Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s128. doi:10.25251/skin.1.supp.127.